Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atrial Fibrillation
New atrial fibrillation research from Tongji University described
May 12th, 2008
" CartoXP and CartoMerge have been used to treat atrial fibrillation (AF) for several years. Our randomized prospective study compared clinical outcomes of these two versions of three dimensional electroanatomic mapping system in guiding catheter ablation for paroxysmal atrial fibrillation (PAF)," scientists writing in the Chinese Medical Journal report. " Eighty-one patients with symptomatic, drug refractory PAF were randomly assigned to CartoMerge group (n=42, mean age (54.5 +/- 13.1) years, history of AF = 3.2 years) or CartoXP group (n=39, mean age (59.8 +/- 15.6) years, history of AF = 2.9 years). All patients underwent 64-slice computed tomography (MSCT) 1...
Source: Biotech Business Week (2008-05-12)
|
